发明名称 HIV-1 ENV DNA VACCINE PLUS PROTEIN BOOST
摘要 The present invention is directed to an effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied. Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime protein boost vaccine regimen. Mice and Guinea pigs were primed with single and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity. Immunization with recombinant Env protein alone induced low-titer binding antibodies with limited neutralization breath. In contrast the synthetic DNA prime protein boost protocol was induced significantly higher antibody binding titers. Furthermore, sera from DNA prime-protein boost groups were able to neutralize a broader range of viruses in a panel of tier 1 clade B viruses as well as multiple tier 1 clade A and clade C viruses. Further investigation of synthetic DNA prime+adaptive EP plus protein boost appears warranted.
申请公布号 EP3068427(A1) 申请公布日期 2016.09.21
申请号 EP20140861787 申请日期 2014.11.06
申请人 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA;INOVIO PHARMACEUTICALS, INC. 发明人 WEINER, DAVID, B.;MUTHUMANI, KARUPPIAH;WISE, MEGAN;YAN, JIAN;BRODERICK, KATE
分类号 A61K39/21;C07K14/16;C12P19/34 主分类号 A61K39/21
代理机构 代理人
主权项
地址